Viewpoint Article by the IAS-USA HIV Drug Resistance Mutations Group Is Now Published at Clinical Infectious Diseases
Newer antiretroviral drugs and the introduction of long-acting regimens have prompted more frequent therapy switches in individuals on suppressive antiretroviral therapy. For these individuals, the use of DNA from peripheral blood lymphocytes for the assessment of HIV drug resistance has become increasingly popular. HIV DNA resistance testing as an alternative to HIV RNA-based analyses in clinical care requires quality-assessment procedures and clinical validation. In addition, HIV DNA testing has some unique challenges that are relevant to the clinical management of people with HIV.
Utilizing HIV Proviral DNA to Assess for the Presence of HIV Drug Resistance, a Viewpoints article recently published at Clinical Infectious Diseases by the world-class experts of the IAS-USA HIV Drug Resistance Mutations Group, provides critical guidance on the use of HIV DNA resistance testing, including technical aspects, potential indications, interpretation, and limitations.
IAS-USA HIV Drug Resistance Mutations Group
Annemarie M. Wensing, MD, PhD, Charlotte Charpentier, PharmD, Vincent Calvez, MD, PhD, Francesca Ceccherini-Silberstein, PhD, Huldrych F. Günthard, MD, Donna M. Jacobsen, BS, Roger Paredes, MD, PhD, Robert W. Shafer, MD, Douglas D. Richman, MD
About the HIV Drug Resistance Mutations Group
Co-chaired by Annemarie M Wensing, MD, PhD, and Douglas D Richman, MD, the IAS-USA HIV Drug Resistance Mutations Group comprises world-class experts who address the issues relevant to clinical virologists and treating physicians for the interpretation of drug-resistance testing or subtype assessment based on DNA analysis, when HIV RNA genotypic assessment is not possible.